{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:25:20Z","timestamp":1792891520617,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40265-026-02303-3","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:11:28Z","timestamp":1773123088000},"page":"581-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"2303_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 report. Available from: https:\/\/goldcopd.org\/2025-gold-report\/. Accessed 24 Feb 2026."},{"issue":"1","key":"2303_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ccm.2013.10.007","volume":"35","author":"G Choudhury","year":"2014","unstructured":"Choudhury G, Rabinovich R, MacNee W. Comorbidities and systemic effects of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):101\u201330. https:\/\/doi.org\/10.1016\/j.ccm.2013.10.007.","journal-title":"Clin Chest Med"},{"issue":"5","key":"2303_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00164-2019","volume":"53","author":"D Singh","year":"2019","unstructured":"Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. https:\/\/doi.org\/10.1183\/13993003.00164-2019.","journal-title":"Eur Respir J"},{"issue":"4","key":"2303_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00239-2023","volume":"61","author":"A Agust\u00ed","year":"2023","unstructured":"Agust\u00ed A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. https:\/\/doi.org\/10.1183\/13993003.00239-2023.","journal-title":"Eur Respir J"},{"key":"2303_CR5","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. GOLD report 2026. Available from: https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/. Accessed 24 Feb 2026."},{"key":"2303_CR6","doi-asserted-by":"publisher","unstructured":"Venkatesan P. GOLD COPD report: 2026 update. Lancet Respir Med. 2025 Nov 26. Online ahead of print. https:\/\/doi.org\/10.1016\/S2213-2600(25)00432-1.","DOI":"10.1016\/S2213-2600(25)00432-1"},{"key":"2303_CR7","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. GOLD report 2026: key changes summary. Available from: https:\/\/goldcopd.org\/wp-content\/uploads\/2025\/11\/KEY-CHANGES-GOLD-2026-10Nov2025.pdf. Accessed 24 Feb 2025."},{"issue":"10","key":"2303_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1164\/rccm.202307-1203OC","volume":"209","author":"AI Ritchie","year":"2024","unstructured":"Ritchie AI, Donaldson GC, Hoffman EA, et al. Structural predictors of lung function decline in young smokers with normal spirometry. Am J Respir Crit Care Med. 2024;209(10):1208\u201318. https:\/\/doi.org\/10.1164\/rccm.202307-1203OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2303_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01289-2024","volume":"11","author":"L Egerod","year":"2025","unstructured":"Egerod L, Ter Haar EAMD, Karsdal MA, et al. Comorbidity profiles in chronic obstructive pulmonary disease: a multicohort study. ERJ Open Res. 2025;11(5):01289\u20132024. https:\/\/doi.org\/10.1183\/23120541.01289-2024.","journal-title":"ERJ Open Res"},{"key":"2303_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107525","volume":"222","author":"BD James","year":"2024","unstructured":"James BD, Greening NJ, Tracey N, et al. Prognostication of co-morbidity clusters on hospitalisation and mortality in advanced COPD. Respir Med. 2024;222:107525. https:\/\/doi.org\/10.1016\/j.rmed.2023.107525.","journal-title":"Respir Med"},{"issue":"1","key":"2303_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-025-03898-1","volume":"25","author":"T Siddharthan","year":"2025","unstructured":"Siddharthan T, Sethi S, Wan E, et al. Progression from GOLD A\/B to GOLD E: a claims analysis of patients with COPD newly initiating inhaled therapy. BMC Pulm Med. 2025;25(1):412. https:\/\/doi.org\/10.1186\/s12890-025-03898-1.","journal-title":"BMC Pulm Med"},{"issue":"7","key":"2303_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-097006","volume":"15","author":"K Rhodes","year":"2025","unstructured":"Rhodes K, Patel D, Duong ML, et al. Future exacerbations and mortality rates among patients experiencing COPD exacerbations: a meta-analysis of results from the EXACOS\/AVOIDEX programme. BMJ Open. 2025;15(7):e097006. https:\/\/doi.org\/10.1136\/bmjopen-2024-097006.","journal-title":"BMJ Open"},{"issue":"5","key":"2303_CR13","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1136\/thorax-2023-220333","volume":"79","author":"AR Jenkins","year":"2024","unstructured":"Jenkins AR, Burtin C, Camp PG, et al. Do pulmonary rehabilitation programmes improve outcomes in patients with COPD posthospital discharge for exacerbation: a systematic review and meta-analysis. Thorax. 2024;79(5):438\u201347. https:\/\/doi.org\/10.1136\/thorax-2023-220333.","journal-title":"Thorax"},{"issue":"11","key":"2303_CR14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","volume":"204","author":"BR Celli","year":"2021","unstructured":"Celli BR, Fabbri LM, Aaron SD, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. Am J Respir Crit Care Med. 2021;204(11):1251\u20138. https:\/\/doi.org\/10.1164\/rccm.202108-1819PP.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2303_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4046\/trd.2024.0155","volume":"88","author":"JY Choi","year":"2025","unstructured":"Choi JY. Non-pharmacologic prevention of acute exacerbation of chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2025;88(3):419\u201330. https:\/\/doi.org\/10.4046\/trd.2024.0155.","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"6","key":"2303_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/13543784.2023.2230138","volume":"32","author":"L Calzetta","year":"2023","unstructured":"Calzetta L, Pistocchini E, Chetta A, Rogliani P, Cazzola M. Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval. Expert Opin Investig Drugs. 2023;32(6):525\u201336. https:\/\/doi.org\/10.1080\/13543784.2023.2230138.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2303_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/thoraxjnl-2020-215167","volume":"76","author":"B David","year":"2021","unstructured":"David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021;76(2):188\u201395. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-215167.","journal-title":"Thorax"},{"issue":"1","key":"2303_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-025-03356-w","volume":"26","author":"C Xie","year":"2025","unstructured":"Xie C, Wang K, Yang K, et al. Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits. Respir Res. 2025;26(1):274. https:\/\/doi.org\/10.1186\/s12931-025-03356-w.","journal-title":"Respir Res"},{"issue":"5","key":"2303_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/14737159.2024.2344777","volume":"24","author":"D Yehia","year":"2024","unstructured":"Yehia D, Leung C, Sin DD. Clinical utilization of airway inflammatory biomarkers in the prediction and monitoring of clinical outcomes in patients with chronic obstructive pulmonary disease. Expert Rev Mol Diagn. 2024;24(5):409\u201321. https:\/\/doi.org\/10.1080\/14737159.2024.2344777.","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"2303_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-02911-3","volume":"24","author":"L Li","year":"2024","unstructured":"Li L, Gong Y, Hou D, et al. Contribution of small airway inflammation to the development of COPD. BMC Pulm Med. 2024;24(1):116. https:\/\/doi.org\/10.1186\/s12890-024-02911-3.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"2303_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.chest.2021.10.046","volume":"161","author":"N Yee","year":"2022","unstructured":"Yee N, Markovic D, Buhr RG, et al. Significance of FEV3\/FEV6 in recognition of early airway disease in smokers at risk of development of COPD: analysis of the SPIROMICS cohort. Chest. 2022;161(4):949\u201359. https:\/\/doi.org\/10.1016\/j.chest.2021.10.046.","journal-title":"Chest"},{"issue":"5","key":"2303_CR22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1164\/rccm.202201-0094OC","volume":"206","author":"RG Buhr","year":"2022","unstructured":"Buhr RG, Barjaktarevic IZ, Quibrera PM, et al. Reversible airflow obstruction predicts future chronic obstructive pulmonary disease development in the SPIROMICS cohort: an observational cohort study. Am J Respir Crit Care Med. 2022;206(5):554\u201362. https:\/\/doi.org\/10.1164\/rccm.202201-0094OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2303_CR23","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1183\/09031936.05.00035205","volume":"26","author":"R Pellegrino","year":"2005","unstructured":"Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948\u201368. https:\/\/doi.org\/10.1183\/09031936.05.00035205.","journal-title":"Eur Respir J"},{"issue":"3","key":"2303_CR24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00561-2019","volume":"54","author":"C Janson","year":"2019","unstructured":"Janson C, Malinovschi A, Amaral AFS, et al. Bronchodilator reversibility in asthma and COPD: findings from three large population studies. Eur Respir J. 2019;54(3):1900561. https:\/\/doi.org\/10.1183\/13993003.00561-2019.","journal-title":"Eur Respir J"},{"issue":"1","key":"2303_CR25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021","volume":"60","author":"S Stanojevic","year":"2022","unstructured":"Stanojevic S, Kaminsky DA, Miller MR, et al. ERS\/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. https:\/\/doi.org\/10.1183\/13993003.01499-2021.","journal-title":"Eur Respir J"},{"issue":"4","key":"2303_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1164\/rccm.202308-1436OC","volume":"209","author":"R Beasley","year":"2024","unstructured":"Beasley R, Hughes R, Agusti A, et al. Prevalence, diagnostic utility and associated characteristics of bronchodilator responsiveness. Am J Respir Crit Care Med. 2024;209(4):390\u2013401. https:\/\/doi.org\/10.1164\/rccm.202308-1436OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"2303_CR27","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/S2213-2600(13)70086-9","volume":"1","author":"PM Calverley","year":"2013","unstructured":"Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med. 2013;1(7):564\u201373. https:\/\/doi.org\/10.1016\/S2213-2600(13)70086-9.","journal-title":"Lancet Respir Med"},{"key":"2303_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/COPD.S96809","volume":"11","author":"HK Koo","year":"2016","unstructured":"Koo HK, Jin KN, Kim DK, Chung HS, Lee CH. Association of incidental emphysema with annual lung function decline and future development of airflow limitation. Int J Chron Obstruct Pulmon Dis. 2016;11:161\u20136. https:\/\/doi.org\/10.2147\/COPD.S96809.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"24","key":"2303_CR29","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.2025.7358","volume":"333","author":"SP Bhatt","year":"2025","unstructured":"COPDGene 2025 Diagnosis Working Group and CanCOLD Investigators, Bhatt SP, Abadi E, et al. A multidimensional diagnostic approach for chronic obstructive pulmonary disease. JAMA. 2025;333(24):2164\u201375. https:\/\/doi.org\/10.1001\/jama.2025.7358.","journal-title":"JAMA"},{"key":"2303_CR30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2147\/COPD.S99793","volume":"11","author":"IG Tsiligianni","year":"2016","unstructured":"Tsiligianni IG, Alma HJ, de Jong C, et al. Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George\u2019s Respiratory Questionnaire cutoff 25 (and 20) as reference. Int J Chron Obstruct Pulmon Dis. 2016;11:1045\u201352. https:\/\/doi.org\/10.2147\/COPD.S99793.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"2303_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01662-7","volume":"22","author":"LY Li","year":"2021","unstructured":"Li LY, Yan TS, Yang J, et al. Impulse oscillometry for detection of small airway dysfunction in subjects with chronic respiratory symptoms and preserved pulmonary function. Respir Res. 2021;22(1):68. https:\/\/doi.org\/10.1186\/s12931-021-01662-7.","journal-title":"Respir Res"},{"key":"2303_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.rmed.2017.04.013","volume":"128","author":"DMG Halpin","year":"2017","unstructured":"Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85\u201391. https:\/\/doi.org\/10.1016\/j.rmed.2017.04.013.","journal-title":"Respir Med"},{"issue":"10","key":"2303_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302318","volume":"19","author":"F Chen","year":"2024","unstructured":"Chen F, Yang M, Wang H, Liu L, Shen Y, Chen L. High blood eosinophils predict the risk of COPD exacerbation: a systematic review and meta-analysis. PLoS ONE. 2024;19(10):e0302318. https:\/\/doi.org\/10.1371\/journal.pone.0302318.","journal-title":"PLoS ONE"},{"issue":"1","key":"2303_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","volume":"206","author":"D Singh","year":"2022","unstructured":"Singh D, Agusti A, Martinez FJ, et al. Blood eosinophils and chronic obstructive pulmonary disease: a global initiative for Chronic Obstructive Lung Disease Science Committee 2022 review. Am J Respir Crit Care Med. 2022;206(1):17\u201324. https:\/\/doi.org\/10.1164\/rccm.202201-0209PP.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2303_CR35","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/15412555.2017.1313827","volume":"14","author":"SH Landis","year":"2017","unstructured":"Landis SH, Suruki R, Hilton E, Compton C, Galwey NW. Stability of blood eosinophil count in patients with COPD in the UK Clinical Practice Research Datalink. COPD: J Chron Obstruct Pulmon Dis. 2017;14(4):382\u20138. https:\/\/doi.org\/10.1080\/15412555.2017.1313827.","journal-title":"COPD: J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"2303_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-21015-4","volume":"15","author":"T Kim","year":"2025","unstructured":"Kim T, Kim Y, Bak SH, et al. Longitudinal parametric response mapping on CT in assessing functional small airway disease and emphysema in COPD. Sci Rep. 2025;15(1):37221. https:\/\/doi.org\/10.1038\/s41598-025-21015-4.","journal-title":"Sci Rep"},{"key":"2303_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108421","volume":"249","author":"A Agusti","year":"2025","unstructured":"Agusti A, Gibson P, Cazzola M. Treatable traits: why, what, how? Respir Med. 2025;249:108421. https:\/\/doi.org\/10.1016\/j.rmed.2025.108421.","journal-title":"Respir Med"},{"issue":"6","key":"2303_CR38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00228-024-03637-1","volume":"80","author":"O Turan","year":"2024","unstructured":"Turan O, Ogan N, Bozkus F, Sar\u0131o\u011flu N, Turan PA, Sat\u0131c\u0131 C. Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients? Eur J Clin Pharmacol. 2024;80(6):847\u201353. https:\/\/doi.org\/10.1007\/s00228-024-03637-1.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"2303_CR39","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.chest.2018.06.022","volume":"154","author":"M Cazzola","year":"2018","unstructured":"Cazzola M, Matera MG. POINT: Should LAMA\/LABA combination therapy be used as initial maintenance treatment for COPD? Yes. Chest. 2018;154(4):746\u20138. https:\/\/doi.org\/10.1016\/j.chest.2018.06.022.","journal-title":"Chest"},{"issue":"3","key":"2303_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.chest.2019.04.012","volume":"156","author":"DM Schumann","year":"2019","unstructured":"Schumann DM, Tamm M, Kostikas K, Stolz D. Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest. 2019;156(3):456\u201365. https:\/\/doi.org\/10.1016\/j.chest.2019.04.012.","journal-title":"Chest"},{"key":"2303_CR41","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.2147\/COPD.S258353","volume":"15","author":"JK Yoon","year":"2020","unstructured":"Yoon JK, Lee JK, Lee CH, et al. The association between eosinophil variability patterns and the efficacy of inhaled corticosteroids in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2020;15:2061\u201370. https:\/\/doi.org\/10.2147\/COPD.S258353.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"2303_CR42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00110-2019","volume":"55","author":"P Jogdand","year":"2020","unstructured":"Jogdand P, Siddhuraj P, Mori M, et al. Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue. Eur Respir J. 2020;55(5):1900110. https:\/\/doi.org\/10.1183\/13993003.00110-2019.","journal-title":"Eur Respir J"},{"key":"2303_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108333","volume":"248","author":"M Cazzola","year":"2025","unstructured":"Cazzola M, Hanania NA, Rogliani P. Comorbidities as treatable traits of chronic airway diseases. Respir Med. 2025;248:108333. https:\/\/doi.org\/10.1016\/j.rmed.2025.108333.","journal-title":"Respir Med"},{"issue":"6","key":"2303_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/15412555.2021.1982886","volume":"18","author":"S Suissa","year":"2021","unstructured":"Suissa S. Triple therapy in COPD: time for adaptive selection trials. COPD J Chronic Obstr Pulm Dis. 2021;18(6):597\u2013601. https:\/\/doi.org\/10.1080\/15412555.2021.1982886.","journal-title":"COPD J Chronic Obstr Pulm Dis"},{"key":"2303_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011600.pub3","volume":"12","author":"WH van Geffen","year":"2023","unstructured":"van Geffen WH, Tan DJ, Walters JA, Walters EH. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023;12:CD011600. https:\/\/doi.org\/10.1002\/14651858.CD011600.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"2303_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206199","volume":"13","author":"E Pirera","year":"2024","unstructured":"Pirera E, Di Raimondo D, Tuttolomondo A. Triple therapy de-escalation and withdrawal of inhaled corticosteroids to dual bronchodilator therapy in patients with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. J Clin Med. 2024;13(20):6199. https:\/\/doi.org\/10.3390\/jcm13206199.","journal-title":"J Clin Med"},{"issue":"5","key":"2303_CR47","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.chest.2017.10.009","volume":"153","author":"O Le Rouzic","year":"2018","unstructured":"Le Rouzic O, Roche N, Cortot AB, et al. Defining the \u201cfrequent exacerbator\u201d phenotype in COPD: a hypothesis-free approach. Chest. 2018;153(5):1106\u201315. https:\/\/doi.org\/10.1016\/j.chest.2017.10.009.","journal-title":"Chest"},{"key":"2303_CR48","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2147\/COPD.S381138","volume":"17","author":"E de Nigris","year":"2022","unstructured":"de Nigris E, Treharne C, Brighton N, Holmgren U, Walker A, Haughney J. Cost-effectiveness of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate dihydrate versus dual therapies in moderate-to-very severe chronic obstructive pulmonary disease: United Kingdom analysis using the ETHOS study. Int J Chron Obstruct Pulmon Dis. 2022;17:2987\u20133000. https:\/\/doi.org\/10.2147\/COPD.S381138.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2303_CR49","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/COPD.S384591","volume":"17","author":"JA Trigueros","year":"2022","unstructured":"Trigueros JA, Garin N, Baloira A, et al. Cost-effectiveness analysis of triple therapy with budesonide\/glycopyrronium\/formoterol fumarate versus dual therapy in patients with chronic obstructive pulmonary disease in Spain. Int J Chron Obstruct Pulmon Dis. 2022;17:2905\u201317. https:\/\/doi.org\/10.2147\/COPD.S384591.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2303_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107694","volume":"231","author":"NA Risebrough","year":"2024","unstructured":"Risebrough NA, Mursleen S, Ndirangu K, et al. The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada: the IMPACT trial. Respir Med. 2024;231:107694. https:\/\/doi.org\/10.1016\/j.rmed.2024.107694.","journal-title":"Respir Med"},{"key":"2303_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/COPD.S345263","volume":"17","author":"M Cazzola","year":"2022","unstructured":"Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG. Beyond dual bronchodilation: triple therapy, when and why. Int J Chron Obstruct Pulmon Dis. 2022;17:165\u201380. https:\/\/doi.org\/10.2147\/COPD.S345263.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2303_CR52","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.2147\/COPD.S424128","volume":"18","author":"M Miravitlles","year":"2023","unstructured":"Miravitlles M, Acharya S, Aggarwal B, et al. Clinical concepts for triple therapy use in patients with COPD: a Delphi consensus. Int J Chron Obstruct Pulmon Dis. 2023;18:1853\u201366. https:\/\/doi.org\/10.2147\/COPD.S424128.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"2303_CR53","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cmi.2022.11.029","volume":"29","author":"C R\u00f8nn","year":"2023","unstructured":"R\u00f8nn C, Sivapalan P, Ekl\u00f6f J, et al. Hospitalization for chronic obstructive pulmonary disease and pneumonia: association with the dose of inhaled corticosteroids: a nation-wide cohort study of 52,100 outpatients. Clin Microbiol Infect. 2023;29(4):523\u20139. https:\/\/doi.org\/10.1016\/j.cmi.2022.11.029.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2303_CR54","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1164\/rccm.201908-1550OC","volume":"201","author":"MA Martinez-Garcia","year":"2020","unstructured":"Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease: a network analysis. Am J Respir Crit Care Med. 2020;201(9):1078\u201385. https:\/\/doi.org\/10.1164\/rccm.201908-1550OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2303_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1164\/rccm.201409-1654PP","volume":"191","author":"E Festic","year":"2015","unstructured":"Festic E, Scanlon PD. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease: a double effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2015;191(2):141\u20138. https:\/\/doi.org\/10.1164\/rccm.201409-1654PP.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2303_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097149","volume":"9","author":"RL DiSantostefano","year":"2014","unstructured":"DiSantostefano RL, Sampson T, Le HV, Hinds D, Davis KJ, Bakerly ND. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS ONE. 2014;9(5):e97149. https:\/\/doi.org\/10.1371\/journal.pone.0097149.","journal-title":"PLoS ONE"},{"issue":"7","key":"2303_CR57","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/jamainternmed.2023.1245","volume":"183","author":"WB Feldman","year":"2023","unstructured":"Feldman WB, Avorn J, Kesselheim AS, Gagne JJ. Chronic obstructive pulmonary disease exacerbations and pneumonia hospitalizations among new users of combination maintenance inhalers. JAMA Intern Med. 2023;183(7):685\u201395. https:\/\/doi.org\/10.1001\/jamainternmed.2023.1245.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"2303_CR58","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56\u20139. https:\/\/doi.org\/10.1164\/rccm.202003-0625ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2303_CR59","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jama.2019.0131","volume":"321","author":"CM Riley","year":"2019","unstructured":"Riley CM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA. 2019;321(8):786\u201397. https:\/\/doi.org\/10.1001\/jama.2019.0131.","journal-title":"JAMA"},{"key":"2303_CR60","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.2147\/COPD.S550144","volume":"20","author":"MG Matera","year":"2025","unstructured":"Matera MG, Calzetta L, Rogliani P, Cazzola M. Multi-criteria decision analysis of biologics in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2025;20:3163\u201373. https:\/\/doi.org\/10.2147\/COPD.S550144.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2303_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108343","volume":"248","author":"P Suter","year":"2025","unstructured":"Suter P, Greig R, Chan R, Lipworth B. Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials. Respir Med. 2025;248:108343. https:\/\/doi.org\/10.1016\/j.rmed.2025.108343.","journal-title":"Respir Med"},{"issue":"7","key":"2303_CR62","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.medj.2024.05.011","volume":"5","author":"MG Matera","year":"2024","unstructured":"Matera MG, Cazzola M. Exploiting the potential of dupilumab in the treatment of eosinophilic COPD. Med. 2024;5(7):652\u20134. https:\/\/doi.org\/10.1016\/j.medj.2024.05.011.","journal-title":"Med"},{"issue":"8","key":"2303_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100784","volume":"6","author":"M Cazzola","year":"2025","unstructured":"Cazzola M, Matera MG. Efficacy without resolution: a critical appraisal of mepolizumab in eosinophilic COPD. Med. 2025;6(8):100784. https:\/\/doi.org\/10.1016\/j.medj.2025.100784.","journal-title":"Med"},{"issue":"1","key":"2303_CR64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","volume":"138","author":"PJ Barnes","year":"2016","unstructured":"Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2016.05.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2303_CR65","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1172\/JCI89768","volume":"126","author":"ME Rothenberg","year":"2016","unstructured":"Rothenberg ME. A hidden residential cell in the lung. J Clin Invest. 2016;126(9):3185\u20137. https:\/\/doi.org\/10.1172\/JCI89768.","journal-title":"J Clin Invest"},{"issue":"14","key":"2303_CR66","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s40265-015-0450-6","volume":"75","author":"M Cazzola","year":"2015","unstructured":"Cazzola M, Rogliani P, Matera MG. Escalation and de-escalation of therapy in COPD: myths, realities and perspectives. Drugs. 2015;75(14):1575\u201385. https:\/\/doi.org\/10.1007\/s40265-015-0450-6.","journal-title":"Drugs"},{"key":"2303_CR67","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2147\/COPD.S275943","volume":"16","author":"JL L\u00f3pez-Campos","year":"2021","unstructured":"L\u00f3pez-Campos JL, Carrasco Hern\u00e1ndez L, Ruiz-Duque B, Reinoso-Arija R, Caballero-Eraso C. Step-up and step-down treatment approaches for COPD: a holistic view of progressive therapies. Int J Chron Obstruct Pulmon Dis. 2021;16:2065\u201376. https:\/\/doi.org\/10.2147\/COPD.S275943.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"2303_CR68","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1164\/rccm.202306-1066ST","volume":"208","author":"CL Rochester","year":"2023","unstructured":"Rochester CL, Alison JA, Carlin B, et al. Pulmonary rehabilitation for adults with chronic respiratory disease: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2023;208(4):e7-26. https:\/\/doi.org\/10.1164\/rccm.202306-1066ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2303_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013040.pub2","volume":"1","author":"NS Cox","year":"2021","unstructured":"Cox NS, Dal Corso S, Hansen H, et al. Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Rev. 2021;1(1):CD013040. https:\/\/doi.org\/10.1002\/14651858.CD013040.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2303_CR70","doi-asserted-by":"publisher","first-page":"713","DOI":"10.4187\/respcare.11656","volume":"69","author":"CL Rochester","year":"2024","unstructured":"Rochester CL. Barriers to pulmonary rehabilitation. Respir Care. 2024;69(6):713\u201323. https:\/\/doi.org\/10.4187\/respcare.11656.","journal-title":"Respir Care"},{"issue":"11","key":"2303_CR71","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S2213-2600(22)00179-5","volume":"10","author":"Y Lacasse","year":"2022","unstructured":"Lacasse Y, Casaburi R, Sliwinski P, et al. Home oxygen for moderate hypoxaemia in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2022;10(11):1029\u201337. https:\/\/doi.org\/10.1016\/S2213-2600(22)00179-5.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"2303_CR72","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa2402638","volume":"391","author":"M Ekstr\u00f6m","year":"2024","unstructured":"Ekstr\u00f6m M, Andersson A, Papadopoulos S, et al. Long-term oxygen therapy for 24 or 15 hours per day in severe hypoxemia. N Engl J Med. 2024;391(11):977\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2402638.","journal-title":"N Engl J Med"},{"issue":"8","key":"2303_CR73","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1159\/000525015","volume":"101","author":"T K\u00f6hnlein","year":"2022","unstructured":"K\u00f6hnlein T, Schwarz SB, Nagel S, Windisch W. Home non-invasive positive pressure ventilation in chronic obstructive pulmonary disease: why, who, and how? Respiration. 2022;101(8):709\u201316. https:\/\/doi.org\/10.1159\/000525015.","journal-title":"Respiration"},{"issue":"5","key":"2303_CR74","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.2019.22343","volume":"323","author":"ME Wilson","year":"2020","unstructured":"Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2020;323(5):455\u201365. https:\/\/doi.org\/10.1001\/jama.2019.22343.","journal-title":"JAMA"},{"issue":"20","key":"2303_CR75","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1001\/jama.2024.15815","volume":"332","author":"Z Luo","year":"2024","unstructured":"Luo Z, Li Y, Li W, et al. Effect of high-intensity vs low-intensity noninvasive positive pressure ventilation on the need for endotracheal intubation in patients with an acute exacerbation of chronic obstructive pulmonary disease: the HAPPEN randomized clinical trial. JAMA. 2024;332(20):1709\u201322. https:\/\/doi.org\/10.1001\/jama.2024.15815.","journal-title":"JAMA"},{"issue":"5","key":"2303_CR76","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/j.chest.2021.06.082","volume":"160","author":"NS Hill","year":"2021","unstructured":"Hill NS, Criner GJ, Branson RD, et al. Optimal NIV Medicare access promotion: patients with COPD: a technical expert panel report from the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. Chest. 2021;160(5):e389\u201397. https:\/\/doi.org\/10.1016\/j.chest.2021.06.082.","journal-title":"Chest"},{"issue":"1","key":"2303_CR77","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/MCP.0000000000001031","volume":"30","author":"N Ravikumar","year":"2024","unstructured":"Ravikumar N, Wagh A, Holden VK, Hogarth DK. Bronchoscopic lung volume reduction in emphysema: a review. Curr Opin Pulm Med. 2024;30(1):58\u201367. https:\/\/doi.org\/10.1097\/MCP.0000000000001031.","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"2303_CR78","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1089\/respcare.12345","volume":"70","author":"A Nathani","year":"2025","unstructured":"Nathani A, Nanah A, Al-Jaghbeer MJ, et al. Multidisciplinary evaluation for COPD management. Respir Care. 2025;70(7):810\u201320. https:\/\/doi.org\/10.1089\/respcare.12345.","journal-title":"Respir Care"},{"issue":"10","key":"2303_CR79","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.202209-1748SO","volume":"208","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Agusti A, Bafadhel M, et al. Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;208(10):1026\u201341. https:\/\/doi.org\/10.1164\/rccm.202209-1748SO.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10356","key":"2303_CR80","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0140-6736(22)01273-9","volume":"400","author":"D Stolz","year":"2022","unstructured":"Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(22)01273-9.","journal-title":"Lancet"},{"issue":"10342","key":"2303_CR81","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(22)00470-6.","journal-title":"Lancet"},{"key":"2303_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1685254","volume":"12","author":"M Wang","year":"2025","unstructured":"Wang M, Li L, Feng M, Liu Z. Advances in artificial intelligence applications for the management of chronic obstructive pulmonary disease. Front Med (Lausanne). 2025;12:1685254. https:\/\/doi.org\/10.3389\/fmed.2025.1685254.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2303_CR83","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1164\/rccm.202303-0400SO","volume":"208","author":"M Cazzola","year":"2023","unstructured":"Cazzola M, Rogliani P, Barnes PJ, et al. An update on outcomes for COPD pharmacological trials: a COPD investigators report: reassessment of the 2008 American Thoracic Society\/European Respiratory Society statement on outcomes for COPD pharmacological trials. Am J Respir Crit Care Med. 2023;208(4):374\u201394. https:\/\/doi.org\/10.1164\/rccm.202303-0400SO.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02303-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02303-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:48:54Z","timestamp":1777002534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02303-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2303"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02303-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mario Cazzola, Jyoti Bajpai, Luigino Calzetta, Maria Gabriella Matera, and Paola Rogliani have no financial or non-financial relationships or activities concerning this article. Mario Cazzola and Luigino Calzetta are Editorial Board members of\n                      Drugs\n                      . Mario Cazzola and Luigino Calzetta were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the initial conception of the manuscript. MC and JB led the drafting and coordinated the revisions of the manuscript among all authors. LC, MGM, and PR critically revised the content on their areas of expertise. All authors approved the final draft.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}